Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Hepatitis

Free Subscription 23.01.2012 1 Arch Virol 1 BMC Gastroenterol 2 Gastroenterology 1 Gut 2 J Hepatol 6 J Med Virol 37 J Viral Hepat 2 J Virol 2 N Engl J Med 2 Vaccine

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Arch Virol

1. LE GAL F , Badur S, Hawajri NA, Akyuz F, et al
   Current hepatitis delta virus type 1 (HDV1) infections in central and eastern Turkey indicate a wide genetic diversity that is probably linked to different HDV1 origins.
   Arch Virol. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   

   
   BMC Gastroenterol

2. LIN KH , Hsu PI, Yu HC, Lin CK, et al
   Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis c and pretreatment low platelet counts.
   BMC Gastroenterol. 2012;12:7.
   PubMed     Text format     Related articles    Abstract available
   
   
   

   
   Gastroenterology

3. THOMAS E , Gonzalez VD, Li Q, Modi AA, et al
   HCV Infection Induces a Unique Hepatic Innate Immune Response Associated with Robust Production of Type III Interferons.
   Gastroenterology. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
4. CHU TW , Kulkarni R, Gane EJ, Roberts SK, et al
   Effect of IL28B Genotype on Early Viral Kinetics during Interferon-Free Treatment of Patients with Chronic Hepatitis C.
   Gastroenterology. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   

   
   Gut

5. OP DE BEECK K , Van den Bergh K, Vermeire S, Decock S, et al
   Immune reactivity to beta-tubulin isotype 5 and vesicular integral-membrane protein 36 in patients with autoimmune gastrointestinal disorders.
   Gut. 2011;60:1601-2.
   PubMed     Text format     Related articles   
   
   
   

   
   J Hepatol

6. PISCHKE S , Gosling J, Engelmann I, Schlue J, et al
   High intrahepatic HHV-6 virus loads but neither CMV nor EBV are associated with decreased graft survival after diagnosis of graft hepatitis.
   J Hepatol. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
7. GUEDJ J , Dahari H, Pohl RT, Ferenci P, et al
   Understanding silibinin's modes of action against HCV using viral kinetic modeling.
   J Hepatol. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   

   
   J Med Virol

8. CHAILLON A , Schnepf N, Jonas M, Mondon K, et al
   Case report: Benefits of quantitative polymerase chain reaction in the clinical management of herpes simplex virus 1 infection with prominent hepatitis and unusual secondary progression.
   J Med Virol. 2012;84:457-61.
   PubMed     Text format     Related articles    Abstract available
   
   
   
9. SHEN L , Gu Y, Sun L, Yang Y, et al
   Development of a hepatitis delta virus antibody assay for study of the prevalence of HDV among individuals infected with hepatitis B virus in China.
   J Med Virol. 2012;84:445-9.
   PubMed     Text format     Related articles    Abstract available
   
   
   
10. HAYASHI K , Katano Y, Kuzuya T, Tachi Y, et al
    Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.
    J Med Virol. 2012;84:438-44.
    PubMed     Text format     Related articles    Abstract available
    
    
    
11. CHARY A , Winters MA, Eisen R, Knight TH, et al
    Quantitation of hepatitis C virus RNA in peripheral blood mononuclear cells in HCV-monoinfection and HIV/HCV-coinfection.
    J Med Virol. 2012;84:431-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
12. YANG HJ , Lee JH, Kim YJ, Yoon JH, et al
    Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
    J Med Virol. 2012;84:424-30.
    PubMed     Text format     Related articles    Abstract available
    
    
    
13. MOHEBBI SR , Amini-Bavil-Olyaee S, Zali N, Damavand B, et al
    Characterization of hepatitis B virus genome variability in Iranian patients with chronic infection, a nationwide study.
    J Med Virol. 2012;84:414-23.
    PubMed     Text format     Related articles    Abstract available
    
    
    

    
    J Viral Hepat

14. KRONENBERGER B , Zeuzem S
    New developments in HCV therapy.
    J Viral Hepat. 2012;19 Suppl 1:48-51.
    PubMed     Text format     Related articles    Abstract available
    
    
    
15. NEGRO F
    Steatosis and insulin resistance in response to treatment of chronic hepatitis C.
    J Viral Hepat. 2012;19 Suppl 1:42-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
16. RUMI M , Aghemo A, Prati GM
    Comparative trials of peginterferon alpha2a and peginterferon alpha2b for chronic hepatitis C.
    J Viral Hepat. 2012;19 Suppl 1:37-41.
    PubMed     Text format     Related articles    Abstract available
    
    
    
17. SEBASTIANI G , Alberti A
    How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C?
    J Viral Hepat. 2012;19 Suppl 1:18-32.
    PubMed     Text format     Related articles    Abstract available
    
    
    
18. SIMON-TALERO M , Buti M, Esteban R
    Severe anaemia related to oseltamivir during treatment of chronic hepatitis C: a new drug interaction?
    J Viral Hepat. 2012;19 Suppl 1:14-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
19. FERENCI P
    Optimal treatment duration for patients with HCV genotype 1 infection.
    J Viral Hepat. 2012;19 Suppl 1:7-13.
    PubMed     Text format     Related articles    Abstract available
    
    
    
20. DEGASPERI E , Aghemo A
    Clinical drivers in naive patient eligibility for treatment of chronic hepatitis C.
    J Viral Hepat. 2012;19 Suppl 1:3-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
21. MARUOKA D , Imazeki F, Arai M, Kanda T, et al
    Longitudinal changes of the laboratory data of chronic hepatitis C patients with sustained virological response on long-term follow-up.
    J Viral Hepat. 2012;19:e97-e104.
    PubMed     Text format     Related articles    Abstract available
    
    
    
22. GROVER VP , Pavese N, Koh SB, Wylezinska M, et al
    Cerebral microglial activation in patients with hepatitis c: in vivo evidence of neuroinflammation.
    J Viral Hepat. 2012;19:e89-e96.
    PubMed     Text format     Related articles    Abstract available
    
    
    
23. BACHMETOV L , Gal-Tanamy M, Shapira A, Vorobeychik M, et al
    Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity.
    J Viral Hepat. 2012;19:e81-e88.
    PubMed     Text format     Related articles    Abstract available
    
    
    
24. RANCE E , Tanner JE, Alfieri C
    Inhibition of IkappaB kinase by thalidomide increases hepatitis C virus RNA replication.
    J Viral Hepat. 2012;19:e73-80.
    PubMed     Text format     Related articles    Abstract available
    
    
    
25. SHI KQ , Cai XH, Xiao DD, Wu SJ, et al
    Tumour necrosis factor-alpha-857T allele reduces the risk of hepatitis B virus infection in an Asian population.
    J Viral Hepat. 2012;19:e66-e72.
    PubMed     Text format     Related articles    Abstract available
    
    
    
26. WAIDMANN O , Bihrer V, Pleli T, Farnik H, et al
    Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection.
    J Viral Hepat. 2012;19:e58-65.
    PubMed     Text format     Related articles    Abstract available
    
    
    
27. HSU CS , Liu CH, Wang CC, Tseng TC, et al
    Impact of hepatitis B virus infection on metabolic profiles and modifying factors.
    J Viral Hepat. 2012;19:e48-57.
    PubMed     Text format     Related articles    Abstract available
    
    
    
28. KWON JH , Jang JW, Lee S, Lee J, et al
    Pretreatment HBeAg level and an early decrease in HBeAg level predict virologic response to entecavir treatment for HBeAg-positive chronic hepatitis B.
    J Viral Hepat. 2012;19:e41-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
29. VAN DE KLUNDERT MA , Cremer J, Kootstra NA, Boot HJ, et al
    Comparison of the hepatitis B virus core, surface and polymerase gene substitution rates in chronically infected patients.
    J Viral Hepat. 2012;19:e34-40.
    PubMed     Text format     Related articles    Abstract available
    
    
    
30. SHI CC , Tjwa ET, Biesta PJ, Boonstra A, et al
    Hepatitis B virus suppresses the functional interaction between natural killer cells and plasmacytoid dendritic cells.
    J Viral Hepat. 2012;19:e26-33.
    PubMed     Text format     Related articles    Abstract available
    
    
    
31. KAWAGUCHI T , Ide T, Itou M, Suetsugu M, et al
    Ischaemic colitis during interferon treatment for chronic hepatitis C: report of two cases and literature review.
    J Viral Hepat. 2012;19:e220-4.
    PubMed     Text format     Related articles    Abstract available
    
    
    
32. SRIVASTAVA A , Yachha SK, Poddar U
    Predictors of outcome in children with acute viral hepatitis and coagulopathy.
    J Viral Hepat. 2012;19:e194-201.
    PubMed     Text format     Related articles    Abstract available
    
    
    
33. GUPTA P , Jagya N, Pabhu SB, Durgapal H, et al
    Immunohistochemistry for the diagnosis of hepatitis E virus infection.
    J Viral Hepat. 2012;19:e177-83.
    PubMed     Text format     Related articles    Abstract available
    
    
    
34. SEBASTIANI G , Tempesta D, Alberti A
    Hepatic iron overload is common in chronic hepatitis B and is more severe in patients coinfected with hepatitis D virus.
    J Viral Hepat. 2012;19:e170-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
35. ALMARIO CV , Vega M, Trooskin SB, Navarro VJ, et al
    Examining hepatitis c virus testing practices in primary care clinics.
    J Viral Hepat. 2012;19:e163-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
36. CHENG JC , Yeh YJ, Huang YH, Liang KH, et al
    Hepatic expression of MxA and OAS1 in an ex vivo liver slice assay independently predicts treatment outcomes in chronic hepatitis C.
    J Viral Hepat. 2012;19:e154-62.
    PubMed     Text format     Related articles    Abstract available
    
    
    
37. CALES P , Zarski JP, Marc Chapplain J, Bertrais S, et al
    Fibrosis progression under maintenance interferon in hepatitis C is better detected by blood test than liver morphometry.
    J Viral Hepat. 2012;19:e143-e153.
    PubMed     Text format     Related articles    Abstract available
    
    
    
38. HAYASHI N , Okanoue T, Tsubouchi H, Toyota J, et al
    Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C.
    J Viral Hepat. 2012;19:e134-e142.
    PubMed     Text format     Related articles    Abstract available
    
    
    
39. MIKI D , Ohishi W, Ochi H, Hayes CN, et al
    Serum PAI-1 is a novel predictor for response to pegylated interferon-alpha-2b plus ribavirin therapy in chronic hepatitis C virus infection.
    J Viral Hepat. 2012;19:e126-e133.
    PubMed     Text format     Related articles    Abstract available
    
    
    
40. CRAXI A , Koutsounas S, Ogurtsov P, Chemello L, et al
    Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response.
    J Viral Hepat. 2012;19:e120-e125.
    PubMed     Text format     Related articles    Abstract available
    
    
    
41. YAMADA I , Suzuki F, Kamiya N, Aoki K, et al
    Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection.
    J Viral Hepat. 2012;19:e112-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
42. HO EY , Ha NB, Ahmed A, Ayoub W, et al
    Prospective study of risk factors for hepatitis C virus acquisition by Caucasian, Hispanic, and Asian American patients.
    J Viral Hepat. 2012;19:e105-11.
    PubMed     Text format     Related articles    Abstract available
    
    
    
43. XIAO C , Qin B, Chen L, Liu H, et al
    Preactivation of the interferon signalling in liver is correlated with nonresponse to interferon alpha therapy in patients chronically infected with hepatitis B virus.
    J Viral Hepat. 2012;19:e1-e10.
    PubMed     Text format     Related articles    Abstract available
    
    
    
44. COTLER SJ , Cotler S, Xie H, Luc BJ, et al
    Characterizing hepatitis B stigma in Chinese immigrants.
    J Viral Hepat. 2012;19:147-52.
    PubMed     Text format     Related articles    Abstract available
    
    
    
45. KATSOUNAS A , Trippler M, Wang B, Polis M, et al
    CCL5 mRNA is a marker for early fibrosis in chronic hepatitis C and is regulated by interferon-alpha therapy and toll-like receptor 3 signalling.
    J Viral Hepat. 2012;19:128-37.
    PubMed     Text format     Related articles    Abstract available
    
    
    
46. VERMEHREN J , Susser S, Lange CM, Forestier N, et al
    Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b.
    J Viral Hepat. 2012;19:120-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
47. JAFFERBHOY H , Miller MH, Dunbar JK, Tait J, et al
    Intravenous drug use: not a barrier to achieving a sustained virological response in HCV infection.
    J Viral Hepat. 2012;19:112-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
48. REAU N , Hamzeh FM, Lentz E, Zhou X, et al
    Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin.
    J Viral Hepat. 2012;19:94-102.
    PubMed     Text format     Related articles    Abstract available
    
    
    
49. ALAVIAN SM , Tabatabaei SV, Behnava B
    Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis.
    J Viral Hepat. 2012;19:88-93.
    PubMed     Text format     Related articles    Abstract available
    
    
    
50. STICKEL F , Helbling B, Heim M, Geier A, et al
    Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C.
    J Viral Hepat. 2012;19:77-87.
    PubMed     Text format     Related articles    Abstract available
    
    
    

    
    J Virol

51. KORTEKAAS J , Oreshkova N, Cobos-Jimenez V, Vloet RP, et al
    Creation of a nonspreading Rift Valley fever virus.
    J Virol. 2011;85:12622-30.
    PubMed     Text format     Related articles    Abstract available
    
    
    
52. LARA E , Billecocq A, Leger P, Bouloy M, et al
    Characterization of wild-type and alternate transcription termination signals in the Rift Valley fever virus genome.
    J Virol. 2011;85:12134-45.
    PubMed     Text format     Related articles    Abstract available
    
    
    

    
    N Engl J Med

53. CHUNG RT
    A watershed moment in the treatment of hepatitis C.
    N Engl J Med. 2012;366:273-5.
    PubMed     Text format     Related articles   
    
    
    
54. LOK AS , Gardiner DF, Lawitz E, Martorell C, et al
    Preliminary study of two antiviral agents for hepatitis C genotype 1.
    N Engl J Med. 2012;366:216-24.
    PubMed     Text format     Related articles    Abstract available
    
    
    

    
    Vaccine

55. CHAVES SS , Fischer G, Groeger J, Patel PR, et al
    Persistence of long-term immunity to hepatitis B among adolescents immunized at birth.
    Vaccine. 2012.
    PubMed     Text format     Related articles    Abstract available
    
    
    
56. PAULKE-KORINEK M , Fischmeister G, Grac A, Rendi-Wagner P, et al
    Persistence of antibodies in 4-8 year old Austrian children after vaccination with hexavalent DTaP-HBV-IPV/Hib and MMR vaccines.
    Vaccine. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: